2012
Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa
Gandhi NR, Weissman D, Moodley P, Ramathal M, Elson I, Kreiswirth BN, Mathema B, Shashkina E, Rothenberg R, Moll AP, Friedland G, Sturm AW, Shah NS. Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa. The Journal Of Infectious Diseases 2012, 207: 9-17. PMID: 23166374, PMCID: PMC3523793, DOI: 10.1093/infdis/jis631.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsCluster AnalysisCross InfectionDrug Therapy, CombinationEthambutolExtensively Drug-Resistant TuberculosisFemaleGenotypeHIV InfectionsHospitals, RuralHumansIsoniazidMaleMutationMycobacterium tuberculosisPolymorphism, Restriction Fragment LengthPrevalencePyrazinamideRetrospective StudiesRifampinSequence Analysis, DNASouth AfricaConceptsDrug-resistant tuberculosisHuman immunodeficiency virusNosocomial transmissionEpidemiologic linkExtensively Drug-Resistant TuberculosisPoor infection controlSmear-positive tuberculosisMultidrug-resistant tuberculosisHigh HIV prevalencePoint-source outbreakGlobal public health threatPublic health threatResistance-determining regionXDR tuberculosisImmunodeficiency virusHIV prevalenceObservational studyInfection controlRural hospitalsPatientsTuberculosisTugela FerryFragment length polymorphism analysisHealth threatRestriction fragment length polymorphism analysisThe immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G, Bamber S, Gengiah S, El-Sadr WM, Friedland G, Abdool Karim S. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Annals Of Internal Medicine 2012, 157: 313-24. PMID: 22944873, PMCID: PMC3534856, DOI: 10.7326/0003-4819-157-5-201209040-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntibiotics, AntitubercularCD4 Lymphocyte CountFemaleHIV InfectionsHumansImmune Reconstitution Inflammatory SyndromeImmunocompromised HostIncidenceKaplan-Meier EstimateMaleProspective StudiesRifampinRisk FactorsSeverity of Illness IndexTuberculosisConceptsImmune reconstitution inflammatory syndromeSequential treatment groupIncidence of IRISReconstitution inflammatory syndromeAntiretroviral therapy initiationART initiationTreatment groupsIRIS incidenceSAPiT trialInflammatory syndromeTherapy initiationTreatment initiationTuberculosis treatmentOpen-label clinical trialCells/LCo-infected patientsEarly ART initiationInitiation of ARTTuberculosis treatment initiationSmear-negative tuberculosisHigher hospitalization ratesWeeks of completionBaseline CD4Antituberculosis treatmentNonambulatory patients
2011
Spread of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa
Moodley P, Shah NS, Tayob N, Connolly C, Zetola N, Gandhi N, Friedland G, Sturm AW. Spread of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa. PLOS ONE 2011, 6: e17513. PMID: 21655324, PMCID: PMC3104985, DOI: 10.1371/journal.pone.0017513.Peer-Reviewed Original ResearchConceptsMDR-TB casesDrug-resistant tuberculosisXDR-TB casesXDR-TBDrug susceptibility test resultsExtensively Drug-Resistant TuberculosisMDR tuberculosis casesMDR-TB patientsXDR-TB patientsCulture-confirmed casesProvincial referral hospitalCross-sectional studyKwaZulu-Natal ProvinceSource of infectionTB casesNumber of hospitalsReferral hospitalSputum cultureTuberculosis casesScotland hospitalsPatientsHealthcare districtsHospitalClinical diagnosisLaboratory databaseRifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients
McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug And Alcohol Dependence 2011, 118: 326-334. PMID: 21596492, PMCID: PMC3272858, DOI: 10.1016/j.drugalcdep.2011.04.013.Peer-Reviewed Original ResearchConceptsBuprenorphine plasma concentrationsWithdrawal symptomsOpiate withdrawalPlasma concentrationsBuprenorphine-maintained patientsBuprenorphine-maintained subjectsDays of rifampinOpioid partial agonistBuprenorphine/naloxoneFirst-line treatmentOpiate withdrawal symptomsSignificant adverse eventsActive metabolite concentrationsOpioid-dependent individualsPlasma buprenorphine concentrationsBuprenorphine pharmacokineticsStable dosesAdverse eventsBuprenorphine doseBuprenorphine therapyAntituberculosis medicationPharmacodynamic interactionsRifampin administrationOpioid dependenceLine treatment
2006
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV
Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. Journal Of Antimicrobial Chemotherapy 2006, 58: 1299-1302. PMID: 17032686, DOI: 10.1093/jac/dkl399.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAnti-HIV AgentsAntibiotics, AntitubercularBenzoxazinesCD4 Lymphocyte CountChromatography, High Pressure LiquidCyclopropanesDidanosineDrug Therapy, CombinationFemaleHIV InfectionsHumansLamivudineLongitudinal StudiesMaleOxazinesRifampinTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsExcellent clinical outcomesEfavirenz concentrationsClinical outcomesAntiretroviral therapyEfavirenz levelsAfrican patientsNon-detectable viral loadSmear-positive pulmonary TBLong-term clinical outcomesAdministration of efavirenzCD4 cell increaseHIV clinical outcomesPlasma efavirenz concentrationsCells/mm3Half of patientsTB regimenPulmonary TBPharmacokinetic interactionsTB outcomesTherapy completionRifampicin administrationViral loadTherapeutic rangePatientsHIV